| Ticker: | AQST |
| Current Price: | $3.91 |
| % Daily Change: | 9.52% |
| Volume (1,000s): | 3,962.40 |
| Average Volume (1,000s): | 0.00 |
| Market Cap (M): | $491.44 |
| 1/2/2024 Price: | $3.58 |
| Change Since Inception: | 9.22% |
Aquestive Therapeutics, Inc.
30 Technology Drive
Warren, NJ 07059
United States
Aquestive Therapeutics, Inc. (Nasdaq: AQST) develops and manufactures medicines delivered on oral film. Using its PharmFilm technology, the company serves as the exclusive manufacturer of four commercialized products that licensees sell across six continents, including Indivior’s Suboxone for opioid dependence and Otter Pharmaceuticals’ Sympazan for a rare form of epilepsy.
Its lead candidate, Anaphylm sublingual film, would be the first oral epinephrine treatment for severe allergic reactions. Aquestive plans to resubmit the application to the FDA in the third quarter of 2026 after a January complete response letter focused on packaging and instructions for use. The company is also advancing AQST-108, a topical gel drawn from its AdrenaVerse epinephrine prodrug platform, and expects to bring Libervant buccal film to the U.S. market in 2027. Incorporated in 2004, Aquestive is headquartered in Warren, New Jersey, with manufacturing in Indiana.